Actinium Pharmaceuticals to Showcase Innovative Cancer Treatments at AACR Annual Meeting 2026
ED
Editorial
Cashu Markets·1 min read
TL;DR
- Actinium Pharmaceuticals will present innovative cancer treatments ATNM-400 and Actimab-A at AACR Annual Meeting 2026.
- The presentations will emphasize the potential advancements of its Ac-225 platform in cancer therapy.
- Actinium is dedicated to improving treatment efficacy while reducing toxicity to healthy tissues.
Actinium Pharmaceuticals, Inc. is set to unveil new preclinical data for its promising radioconjugate ATNM-400 and its acute myeloid leukemia (AML) treatment, Actimab-A, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. Scheduled from April 17-22, 2026, in San Diego, California, these presentations will showcase critical findings that highlight the first-in-class efficacy of ATNM-400 across various solid tumor models. CEO Sandesh Seth emphasizes the versatility and potential of the Ac-225 platform, particularly its effectiveness against tumors that are resistant to standard therapies.